TIDMAPH

RNS Number : 2212O

Alliance Pharma PLC

05 August 2014

 
 For immediate release                                                         5 August 2014

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Notification of Interim Results

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its interim results for the six months ended 30 June 2014 on Wednesday 10 September 2014.

A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For more information, or to register attendance, please contact Buchanan on 020 7466 5000.

For further information:

 
 Alliance Pharma plc                    + 44 (0) 1249 466966 
 John Dawson, Chief Executive 
 Richard Wright, Finance Director 
 
 Buchanan                              + 44 (0) 20 7466 5000 
 Mark Court / Fiona Henson / Sophie 
  Cowles 
 
 Numis Securities Limited              + 44 (0) 20 7260 1000 
 Nominated Adviser: Michael Meade / 
  Freddie Barnfield 
 Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORPIMFTMBBMBMI

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.